Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Calogero Cammà; Salvatore Petta; Giuseppe Cabibbo; Matteo Ruggeri; Marco Enea; Raffaele Bruno; Rosa Anna Bruno; Vincenza Capursi; Antonio Gasbarrini; Alfredo Alberti; Antonio Craxì

doi:10.1016/j.jhep.2013.05.019

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Calogero Cammà
, Salvatore Petta
, Giuseppe Cabibbo
, Matteo Ruggeri
, Marco Enea
, Raffaele Bruno
, Rosa Anna Bruno
, Vincenza Capursi
, Antonio Gasbarrini
, Alfredo Alberti
, Antonio Craxì

University of Palermo
University of Pavia
Venetian Institute of Molecular Medicine

Research output: Contribution to journal › Article

37 Citations (Scopus)

Abstract

Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.

Original language	English
Pages (from-to)	658-666
Number of pages	9
Journal	Journal of Hepatology
Volume	59
DOIs	https://doi.org/10.1016/j.jhep.2013.05.019
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BOC
Boceprevir
CHC
Cost-effectiveness
DT
G1
ICER
NR
PAR
PI
PegIFN
RBV
RR
TVR
Telaprevir
boceprevir
chronic hepatitis C
dual therapy
genotype 1
incremental cost-effectiveness ratio
non-response
partial response
pegylated interferon
protease inhibitors
relapse
ribavirin
telaprevir

Access to Document

10.1016/j.jhep.2013.05.019

Cite this

@article{1d08198e7db647ebb30ab52c0722777b,

title = "Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C",

abstract = "Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.",

keywords = "BOC, Boceprevir, CHC, Cost-effectiveness, DT, G1, ICER, NR, PAR, PI, PegIFN, RBV, RR, TVR, Telaprevir, boceprevir, chronic hepatitis C, dual therapy, genotype 1, incremental cost-effectiveness ratio, non-response, partial response, pegylated interferon, protease inhibitors, relapse, ribavirin, telaprevir, BOC, Boceprevir, CHC, Cost-effectiveness, DT, G1, ICER, NR, PAR, PI, PegIFN, RBV, RR, TVR, Telaprevir, boceprevir, chronic hepatitis C, dual therapy, genotype 1, incremental cost-effectiveness ratio, non-response, partial response, pegylated interferon, protease inhibitors, relapse, ribavirin, telaprevir",

author = "Calogero Camm{\`a} and Salvatore Petta and Giuseppe Cabibbo and Matteo Ruggeri and Marco Enea and Raffaele Bruno and Bruno, \{Rosa Anna\} and Vincenza Capursi and Antonio Gasbarrini and Alfredo Alberti and Antonio Crax{\`i}",

year = "2013",

doi = "10.1016/j.jhep.2013.05.019",

language = "English",

volume = "59",

pages = "658--666",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

AU - Cammà, Calogero

AU - Petta, Salvatore

AU - Cabibbo, Giuseppe

AU - Ruggeri, Matteo

AU - Enea, Marco

AU - Bruno, Raffaele

AU - Bruno, Rosa Anna

AU - Capursi, Vincenza

AU - Gasbarrini, Antonio

AU - Alberti, Alfredo

AU - Craxì, Antonio

PY - 2013

Y1 - 2013

N2 - Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.

AB - Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.

KW - BOC

KW - Boceprevir

KW - CHC

KW - Cost-effectiveness

KW - DT

KW - G1

KW - ICER

KW - NR

KW - PAR

KW - PI

KW - PegIFN

KW - RBV

KW - RR

KW - TVR

KW - Telaprevir

KW - boceprevir

KW - chronic hepatitis C

KW - dual therapy

KW - genotype 1

KW - incremental cost-effectiveness ratio

KW - non-response

KW - partial response

KW - pegylated interferon

KW - protease inhibitors

KW - relapse

KW - ribavirin

KW - telaprevir

KW - BOC

KW - Boceprevir

KW - CHC

KW - Cost-effectiveness

KW - DT

KW - G1

KW - ICER

KW - NR

KW - PAR

KW - PI

KW - PegIFN

KW - RBV

KW - RR

KW - TVR

KW - Telaprevir

KW - boceprevir

KW - chronic hepatitis C

KW - dual therapy

KW - genotype 1

KW - incremental cost-effectiveness ratio

KW - non-response

KW - partial response

KW - pegylated interferon

KW - protease inhibitors

KW - relapse

KW - ribavirin

KW - telaprevir

UR - http://hdl.handle.net/10807/52235

U2 - 10.1016/j.jhep.2013.05.019

DO - 10.1016/j.jhep.2013.05.019

M3 - Article

SN - 0168-8278

VL - 59

SP - 658

EP - 666

JO - Journal of Hepatology

JF - Journal of Hepatology

ER -

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this